DEVIDERMA

Active Private limited companyfounded 2009active for 17 yearsGanzenbos 24, 1730 AsseKBO/BCE: BE 0810.861.503

DEVIDERMA

Follow Report Compare

Overview

Lifetime

17 annual accounts with figures on one time axis

Compare with

peak €100,586 (2021)

€47,983▼ 38.0%

lowest -€12,941 (2010)

€28,788▼ 41.3%

peak €245,946 (2024)

€200,775▼ 18.4%

€107,718▲ 14×

Board1 name since 2020

1 director

Documentsfilings and deeds

03-06-202658 days before the deadline

2025micro format

Gross margin from €77,430 to €47,983Result from €49,039 to €28,788Dividend €73,958Equity from €245,946 to €200,775Debts from €7,872 to €107,718Investments €159,438

Key points

from the 2025 annual accounts

Equity

€200,775 ▼ 18.4%

DEVIDERMA paid out €73,958 in dividends. That is 257% of the 2025 profit.

Turnover

≈ €150,000 estimated

The micro format states no turnover.

Debts

€107,718 ▲ 14×

Other debts

+2,638

Taxes and wages

+778

The rest

+96,430

Debts rose by €99,846 in 2025. A dividend stands under other debts on the balance sheet date until it is paid.

Investments

€159,438 16.8 × depreciation

Green is investment, beige is depreciation. Land and buildings stand 536.7% higher than in 2024.

Liquidity

9.89 was 29.73 in 2024

Short-term debts rose from €7,872 to €14,030.

Filings

17 annual accounts since 2009

The last five annual accounts were filed 39 to 97 days before the end of the period.

Checked score

Bankruptcy probability within 12 months

Financial strength

Score breakdown

Comparable companies, two years later

In July 2024, 34,721 companies had the same profile as DEVIDERMA has now. Each dot stands for 87 companies, two years later.

95.3%

were still trading

4.0%

stopped another way

0.7%

went bankrupt

Micro
10 to 20 years old
solvency 30% or more
a profit of 5% of the balance sheet or more

Test of the method

The method was tested on the 497,762 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.

The companies in ten equal groups, from the lowest to the highest expected share
Group	Expected	Actual
1	0.2%	0.2%
2	0.3%	0.5%
3	0.5%	0.6%
4	0.7%	0.8%
5	0.9%	0.9%
6	1.3%	1.5%
7	1.6%	1.8%
8	1.8%	1.8%
9	2.9%	3.1%
10	5.6%	6.1%

A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.

This is an observation about 34,721 companies, not a prediction for DEVIDERMA. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.

Credit verdict

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Board and ownership

Director

Board & ownership

Recent changes

18-11-2025

Registered in the Peppol Directory Reachable for e-invoices through 0208:0810861503

13-12-2023

Appointment: (director) Gazette deed

07-07-2009

First establishment Ganzenbos 24, Asse

01-04-2009

Incorporation published on 09-04-2009 · Gazette deed

All 29 events

Comparable companies

same main activity, similar in size and age

Company
DEVIDERMA Asse	€308,493	€47,983	65.1%	-
DOKTER L.DEVALKENEER KINDERPSYCHIATRIE Asse	€314,639	€52,559	65.3%	-
DOKTER DIETER PODEVYN - ALGEMENE GENEESKUNDE Asse	€290,503	€54,585	65.8%	-
DOCTEUR ISABELLE STAS Liège	€336,023	€44,678	43.0%	-
Docteur Karole KOSTYLA Nivelles	€270,632	€49,251	82.0%	-
Dr. VAN AKEN DAVID Schoten	€304,885	€55,167	81.2%	-
Dr Karina PHILIPS , Dermatologie Steenokkerzeel	€309,169	€54,658	65.0%	-

These companies have the same main activity as DEVIDERMA: specialist medical practice (NACE 86220). They are comparable in size and age: total assets between €271,000 and €336,000, founded between 2007 and 2011.

Official details

Source: KBO

Status: Active since 01-04-2009Normal situation
Activity: Specialist medical practiceNACE 86220and 1 other
Establishment unit: 2.182.243.4441730 Asse, since 07-07-2009
Financial year end: 31 December
Peppol: Reachable since 18-11-2025

Company details

Annual accounts 2025

: €47,983▼ 38.0%
: €28,788▼ 41.3%
: €200,775▼ 18.4%
: €308,493▲ 21.5%
Filing: Filed on 03-06-2026, 58 days before the end of the filing period

Financials

Insights on DEVIDERMA

DEVIDERMA files the micro format. That format states no turnover. The gross margin rose from €41,007 in 2009 to €47,983 in 2025.

The balance sheet grew most from 2023 to 2025 through fixed assets, financed with long-term debt.

Sources: KBO register, filings at the National Bank, Belgian Official Gazette.

Financials

Annual accounts 2025

micro format, filed on 03-06-2026, 58 days before the deadline

€47,983

▼ 38.0%

€37,573

▼ 41.3%

€47,074

▼ 38.7%

€38,288

▼ 38.2%

65.1%

▼ 31.8 percentage points

9.89

▼ 19.84

Turnover and EBIT margin are not published. The micro format does not require them. The turnover shown is an estimate from the gross margin.

Turnover ≈ €150,000. Estimated: probably between €110,000 and €210,000.

Money flows

no detail for 2025

Balance sheet

balance sheet total €308,493 on 31-12-2025

What the company ownsHow it is paid for

in euro

Position in the sector

Compare with sector

65.1%

Higher than 52% of 21,330 companies in 2025.

9.89

Higher than 83% of 20,880 companies in 2025.

9.3%

Higher than 24% of 21,180 companies in 2025.

DEVIDERMA Middle half of the sector 80% of the sector Micro accounts in human health (NACE 86)

Net result: middle half · Equity: middle half · Balance sheet total: middle half · Working capital: middle half

Filed annual accounts

as filed with the National Bank, click a year to choose it

Line	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009
Balance sheet: assets
`20/58`	308,493	253,818	211,191	191,642	158,888	122,494	160,201	151,794	139,883	158,996	185,680	205,925	223,317	215,803	202,113	218,705	160,540
`21/28`	169,736	19,798	32,672	35,094	57,243	82,632	88,454	117,346	112,810	142,644	140,996	145,343	174,557	166,877	164,203	183,622	88,343
`21`	-	-	-	-	-	-	-	-	-	-	-	-	59	119	178	237	-
`22/27`	169,736	19,798	32,672	35,094	57,243	82,632	88,454	117,346	112,810	142,644	140,996	145,343	174,498	166,758	164,025	183,385	88,343
`22`	126,057	19,798	32,049	31,797	43,177	57,377	54,413	75,487	96,561	114,507	101,083	118,648	137,594	152,489	150,203	168,011	87,840
`23`	1,677	-	-	2,049	4,099	6,568	9,533	8,938	15,396	21,185	27,967	9,345	12,958	12,645	11,384	12,124	503
`24`	42,002	-	624	1,248	9,967	18,687	24,509	32,921	853	6,953	11,946	17,351	23,947	1,625	2,437	3,250	-
`29/58`	138,757	234,020	178,519	156,548	101,645	39,862	71,746	34,448	27,073	16,352	44,684	60,582	48,760	48,926	37,910	35,083	72,197
`29`	53,448	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
`291`	53,448	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
`40/41`	8,652	2,109	4,309	80	-	-	3,051	2,449	3,361	4,500	3,791	4,187	5,851	13,389	8,463	15,697	11,389
`40`	-	-	-	80	-	-	3,051	2,449	3,361	4,500	3,791	3,332	5,851	13,389	8,457	9,592	11,389
`41`	8,652	2,109	4,309	-	-	-	-	-	-	-	-	855	-	-	6	6,106	-
`50/53`	50,000	50,000	100,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-
`54/58`	22,460	181,661	73,960	156,468	101,645	39,862	68,696	31,999	23,712	11,851	40,894	54,417	42,747	35,466	29,448	15,460	28,537
`490/1`	4,197	250	250	-	-	-	-	-	-	-	-	1,978	162	71	-	3,926	32,272
Balance sheet: equity and liabilities
`10/49`	308,493	253,818	211,191	191,642	158,888	122,494	160,201	151,794	139,883	158,996	185,680	205,925	223,317	215,803	202,113	218,705	160,540
`10/15`	200,775	245,946	206,003	156,263	110,091	64,500	46,668	43,811	34,716	29,174	21,999	14,321	51,149	39,411	14,294	10,837	23,779
`10/11`	12,400	12,400	12,400	12,400	12,400	12,400	12,400	12,400	12,400	12,400	12,400	12,400	12,400	12,400	12,400	12,400	12,400
`100`	-	-	-	-	-	-	18,600	18,600	18,600	18,600	18,600	18,600	18,600	18,600	18,600	18,600	18,600
`101`	-	-	-	-	-	-	6,200	6,200	6,200	6,200	6,200	6,200	6,200	6,200	6,200	6,200	6,200
`13`	188,315	233,485	193,542	143,802	97,630	52,039	34,208	31,351	22,255	16,713	9,538	1,860	37,860	27,011	1,894	11,379	11,379
`130/1`	-	-	-	1,860	1,860	1,860	-	-	-	-	-	-	-	-	-	-	-
`130`	-	-	-	-	-	-	1,860	1,860	1,860	1,860	1,860	1,860	1,860	1,860	1,860	1,860	1,860
`1311`	-	-	-	1,860	1,860	1,860	-	-	-	-	-	-	-	-	-	-	-
`133`	188,315	233,485	193,542	141,942	95,770	50,179	32,348	29,491	20,395	14,853	7,678	-	36,000	25,151	34	9,519	9,519
`14`	61	61	61	61	61	61	61	61	61	61	61	61	889	-	-	-12,941	-
`17/49`	107,718	7,872	5,189	35,379	48,797	57,994	113,533	107,983	105,167	129,821	163,681	191,604	172,169	176,392	187,818	207,867	136,761
`17`	93,688	-	-	3,703	16,924	31,272	45,919	74,504	74,669	97,015	105,624	126,320	146,270	149,001	163,728	177,898	120,459
`170/4`	93,688	-	-	3,703	16,924	31,272	45,919	74,504	74,669	97,015	105,624	126,320	146,270	149,001	163,728	177,898	120,459
`42/48`	14,030	7,872	5,189	31,676	31,873	26,722	67,614	33,478	30,498	32,806	58,057	65,284	25,899	27,390	24,091	29,969	16,303
`42`	4,757	-	3,703	13,221	14,348	14,647	28,585	28,699	22,346	25,392	20,696	19,950	19,232	14,726	14,146	13,561	8,978
`44`	1,945	3,960	208	1	2,278	1,186	1,206	1,799	3,052	213	30,311	81	3,047	5,519	334	2,766	2,611
`440/4`	1,945	3,960	208	1	2,278	1,186	1,206	1,799	3,052	213	30,311	81	3,047	5,519	334	2,766	2,611
`45`	4,622	3,844	1,278	9,124	7,846	4,261	14,625	1,224	3,932	1,822	1,997	-	666	3,469	1,010	11,776	3,776
`450/3`	4,622	-	1,278	9,124	7,846	868	11,252	1,224	607	1,822	1,997	-	666	3,469	1,010	3,776	3,776
`454/9`	-	3,844	-	-	-	3,393	3,373	-	3,325	-	-	-	-	-	-	8,000	-
`47/48`	2,706	68	-	9,330	7,401	6,628	23,197	1,756	1,168	5,380	5,053	45,254	2,955	3,677	8,601	1,866	937
Income statement
`70`	-	-	-	-	-	-	-	-	-	153,550	-	-	-	-	-	82,836	-
`76A`	-	1,203	-	5,608	2,014	5,851	-	-	-	-	-	-	-	-	-	-	-
`9900`	47,983	77,430	91,538	96,843	100,586	51,334	73,410	53,088	49,547	51,837	50,906	45,869	57,149	67,939	37,944	15,442	41,007
`60/61`	-	-	-	-	-	-	-	-	-	104,396	-	-	-	-	-	67,499	-
`630`	9,500	12,874	14,924	22,149	25,389	26,151	39,138	37,446	35,062	34,573	32,046	29,214	30,318	23,703	21,498	21,717	10,913
`640/8`	909	600	631	581	568	889	718	837	692	640	1,295	1,267	1,309	1,507	546	550	11,987
`9901`	37,573	63,956	75,983	74,114	74,628	24,294	33,554	14,806	13,793	16,624	17,565	15,387	25,522	42,729	15,900	-6,825	18,107
`75/76B`	3,645	4,721	1,540	1,400	1,372	1,382	10,830	2,518	13	83	209	182	71	182	51	38	-
`75`	3,645	3,121	-	-	2	22	7,009	14	13	83	209	182	71	182	51	38	-
`76B`	-	1,600	1,540	1,400	1,370	1,360	3,820	2,503	-	-	-	-	-	-	-	-	-
`65/66B`	718	810	1,111	1,889	1,887	2,473	3,315	4,003	4,655	5,197	5,566	6,274	6,969	7,098	7,677	6,154	2,952
`65`	718	810	1,111	1,889	1,887	2,473	3,315	4,003	4,655	5,197	5,566	6,274	6,969	7,098	7,677	6,154	2,952
`9903`	40,501	67,866	76,412	73,625	74,113	23,203	41,069	13,321	9,151	11,509	12,208	9,296	18,624	35,813	8,273	-12,941	15,155
`67/77`	11,713	18,827	21,131	20,278	20,844	5,371	9,382	4,225	3,609	4,334	4,529	3,624	5,274	9,085	6	-	3,776
`9904`	28,788	49,039	55,281	53,347	53,269	17,832	31,687	9,096	5,542	7,175	7,678	5,672	13,350	26,728	8,267	-12,941	11,379
`9905`	28,788	49,039	55,281	53,347	53,269	17,832	31,687	9,096	5,542	7,175	7,678	5,672	13,350	26,728	8,267	-12,941	11,379
Appropriation of the result
`9906`	28,848	49,100	55,342	53,408	53,330	17,892	31,748	9,156	5,602	7,236	7,739	6,561	13,350	26,728	-4,674	-12,941	11,379
`14P`	61	61	61	61	61	-	-	-	-	-	-	-	-	-	-	-	-
`791/2`	73,958	9,096	5,542	7,175	7,678	-	-	-	-	-	-	36,000	-	-	9,484	-	-
`691/2`	28,788	49,039	55,281	53,347	53,269	17,832	2,857	9,096	5,542	7,175	7,678	-	10,849	25,116	-	-	11,379
`6920`	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,860
`6921`	28,788	49,039	55,281	53,347	53,269	17,832	2,857	9,096	5,542	7,175	7,678	-	10,849	25,116	-	-	9,519
`694/7`	73,958	9,096	5,542	7,175	7,678	-	28,830	-	-	-	-	42,500	1,612	1,612	4,810	-	-
`694`	73,958	-	-	-	-	-	28,830	-	-	-	-	42,500	1,612	1,612	4,810	-	-
`695`	-	9,096	5,542	7,175	7,678	-	-	-	-	-	-	-	-	-	-	-	-
Document	PDF	PDF	PDF	PDF	PDF	PDF	PDF	PDF	PDF	PDF	PDF	PDF	PDF	PDF	PDF	PDF	PDF

The notes to these accounts have 8 items, including the statement of assets and debts, the cost breakdown and rights and commitments. You find them in the filed accounts (PDF).

Source: Annual accounts 2025 (PDF), filed on 03-06-2026.

Download as CSV

Filings

each dot is a set of accounts, on the day it reached the National Bank

Financial year	Type	Filed	Reference	Document
31-12-2025	micro format	03-06-2026	2026-00134537	PDF
31-12-2024	micro format	27-05-2025	2025-00107740	PDF
31-12-2023	micro format	25-04-2024	2024-00069488	PDF
31-12-2022	micro format	22-06-2023	2023-00147864	PDF
31-12-2021	micro format	30-05-2022	2022-20038062	PDF
31-12-2020	micro format	31-05-2021	2021-16000266	PDF
31-12-2019	micro format	29-05-2020	2020-13600158	PDF
31-12-2018	micro format	29-05-2019	2019-15000157	PDF
31-12-2017	micro format	31-05-2018	2018-15100370	PDF
31-12-2016	micro format	24-05-2017	2017-13900197	PDF
31-12-2015	abbreviated format	10-05-2016	2016-11600420	PDF
31-12-2014	abbreviated format	29-04-2015	2015-10800070	PDF
31-12-2013	abbreviated format	30-04-2014	2014-11300430	PDF
31-12-2012	abbreviated format	17-05-2013	2013-12300231	PDF
31-12-2011	abbreviated format	04-05-2012	2012-10500324	PDF
31-12-2010	abbreviated format	26-04-2011	2011-09100109	PDF
31-12-2009	abbreviated format	03-05-2010	2010-11000250	PDF

Subsidies and aid

Flemish government 2024 to 2025, 2 entries, €2,328 awarded, €2,328 paid

Subsidie voor opleiding en advies voor kmo's en zelfstandigen (kmo-portefeuille)

€2,328

Year	Entries	Awarded	Paid
2025	1	€1,125	€1,125
2024	1	€1,203	€1,203

Key figures and ratios

per financial year, computed from the annual accounts

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009
47,074	76,830	90,907	96,263	100,017	50,445	72,692	52,252	48,855	51,197	49,611	44,602	55,840	66,432	37,398	14,892	29,020
38,288	61,913	70,205	75,496	78,659	43,983	70,825	46,542	40,603	41,748	39,725	34,886	43,668	50,431	29,765	8,775	22,292
159,438	0	12,502	0	0	20,329	10,247	41,982	5,228	36,221	27,699	0	37,999	26,377	2,079	116,996	98,306
-159,201	107,701	-82,508	54,823	61,783	-28,834	36,697	8,287	11,861	-29,043	-13,523	11,670	7,281	6,019	13,988	-13,077	-
124,728	226,148	173,330	124,872	69,772	13,140	4,133	970	-3,425	-16,455	-13,373	-4,703	22,861	21,536	13,819	5,114	55,895
-	-	-	-	-	-	-	-	-	10.8%	-	-	-	-	-	-8.2%	-
65.1%	96.9%	97.5%	81.5%	69.3%	52.7%	29.1%	28.9%	24.8%	18.3%	11.8%	7.0%	22.9%	18.3%	7.1%	5.0%	14.8%
9.89	29.73	34.41	4.94	3.19	1.49	1.06	1.03	0.89	0.50	0.77	0.93	1.88	1.79	1.57	1.17	4.43
0.54	0.03	0.03	0.23	0.44	0.90	2.43	2.46	3.03	4.45	7.44	13.38	3.37	4.48	13.14	19.18	5.75
14.3%	19.9%	26.8%	34.1%	48.4%	27.6%	67.9%	20.8%	16.0%	24.6%	34.9%	39.6%	26.1%	67.8%	57.8%	-119.4%	47.9%
9.3%	19.3%	26.2%	27.8%	33.5%	14.6%	19.8%	6.0%	4.0%	4.5%	4.1%	2.8%	6.0%	12.4%	4.1%	-5.9%	7.1%
65.58	94.81	81.84	50.97	53.00	-	-	-	-	-	-	-	-	-	-	-	-
-	-	-	-	-	-	-	-	-	11 days	-	-	-	-	-	42 days	-
-	-	-	-	-	-	-	-	-	1 day	-	-	-	-	-	15 days	-

A Belgian filing has no cash-flow statement. Cash flow is therefore an approximation, derived from the income statement. Investment is the acquisitions in the notes and, without them, the balance-sheet move.

Investments

fixed assets acquired

Item	2025	2024	2023	2022	2021
Tangible fixed assets	€159,438	-	€12,502	-	-
	€9,500	€12,874	€14,924	€22,149	€25,389

Source: notes to the 2021 to 2025 annual accounts (statement of fixed assets)

Insights on DEVIDERMA

The operating result for 2025 is 41% lower than in 2024 and the lowest since 2020. It is the second fall in a row.

Debt's share of the balance-sheet total rises from 3.1% to 34.9%. Equity is lower and debt is higher.

Board & ownership

Board

1 director, no change since 2020

Director

appointed by deed of 13-12-2023 term without a fixed end

listed in the 2025 annual accounts, filed on 03-06-2026

Office holders in the KBO →

Mandates through the years

1 name, the dashed line is today

Director

Board

Mandates as a list

- Director, appointed by deed of 13-12-2023, still in office

See the board, name and registered office on a given date →

Control

See the annual accounts at the National Bank and the publications in the Belgian Official Gazette.

Capital

Contribution: €12,400
Source: 2025 annual accounts

Articles of association

deed of 13-12-2023 (in Dutch)

Duration: Unlimited
Board rule: At least 1 director
Transfer restriction: “Helft overdrager,helft kopers naar evenredigheid verworven aandelen, werkelijke waarde op dag overdracht”
Annual meeting: 23 April at 14:00

Network & group

No group

DEVIDERMA has no parent and no holdings in its annual accounts. is the only director. DEVIDERMA shares no director with another company.

Timeline

29 events since 2009

Board

Filings

Financial

Establishments

201020122014201620182020202220242026

Deadline for the 2026 accounts: 31-07-2027

2026

03-06-2026

Annual accounts 2025 filed PDFmicro format · 58 days before the deadline

2025

18-11-2025

Registered in the Peppol Directory Reachable for e-invoices through 0208:0810861503

27-05-2025

Annual accounts 2024 filed PDFmicro format · 65 days before the deadline

2024

25-04-2024

Annual accounts 2023 filed PDFmicro format · 97 days before the deadline

2023

31-12-2023

Highest result from 2009 to 2025 net €55,281 ▲3.6% The operating result of €75,983 and the net result of €55,281 are both a record.

31-12-2023

Liquidity more than 6 times current ratio 34.41 The current ratio rises from 4.94 to 34.41. Short-term debt falls from €31,676 to €5,189.

31-12-2023

Equity above €200,000 equity €206,003 ▲31.8% After 13 profitable years in a row, equity reaches €206,003.

13-12-2023

Appointment: (director)1 point ▸

Director appointment,
The deed holds 3 more points.

Open the deed in the Belgian Official Gazette

22-06-2023

Annual accounts 2022 filed PDFmicro format · 39 days before the deadline

2022

31-12-2022

Equity above €150,000 equity €156,263 ▲41.9% After 12 profitable years in a row, equity reaches €156,263.

30-05-2022

Annual accounts 2021 filed PDFmicro format · 62 days before the deadline

2021

31-12-2021

Liquidity more than doubled current ratio 3.19 The current ratio rises from 1.49 to 3.19.

31-12-2021

Equity above €100,000 equity €110,091 ▲70.7% After 11 profitable years in a row, equity reaches €110,091.

31-05-2021

Annual accounts 2020 filed PDFmicro format · 61 days before the deadline

2020

29-05-2020

Annual accounts 2019 filed PDFmicro format · 63 days before the deadline

2019

29-05-2019

Annual accounts 2018 filed PDFmicro format · 63 days before the deadline

2018

31-05-2018

Annual accounts 2017 filed PDFmicro format · 61 days before the deadline

2017

24-05-2017

Annual accounts 2016 filed PDFmicro format · 68 days before the deadline

2016

10-05-2016

Annual accounts 2015 filed PDFabbreviated format · 82 days before the deadline

2015

29-04-2015

Annual accounts 2014 filed PDFabbreviated format · 93 days before the deadline

2014

30-04-2014

Annual accounts 2013 filed PDFabbreviated format · 92 days before the deadline

2013

17-05-2013

Annual accounts 2012 filed PDFabbreviated format · 75 days before the deadline

2012

04-05-2012

Annual accounts 2011 filed PDFabbreviated format · 88 days before the deadline

2011

31-12-2011

Back to profit net €8,267 The net result is €8,267, after one loss-making year.

26-04-2011

Annual accounts 2010 filed PDFabbreviated format · 96 days before the deadline

2010

31-12-2010

Weakest financial year net -€12,941 The net result drops to -€12,941, the lowest from 2009 to 2025. It recovers the following year.

03-05-2010

Annual accounts 2009 filed PDFabbreviated format · 89 days before the deadline

2009

07-07-2009

First establishment Ganzenbos 24, Asse

01-04-2009

Incorporation PDFpublished on 09-04-2009

Financial milestones sit on the financial year-end date, not the filing date.

Sources: Publications in the Belgian Official Gazette Filings with the National Bank

History

On 1 April 2009, DEVIDERMA was incorporated.¹ is director of the company, appointed by deed of 13-12-2023.² Total assets went from €151,794 in 2018 to €308,493 in 2025.³

Company details

Identity

Enterprise number: 0810.861.503
VAT number: BE 0810.861.503
Peppol ID: 0208:0810861503
Other Peppol ID: 9925:BE0810861503
Legal form: Private limited company
Status: Active, normal situation
Founded: 01-04-2009
Financial year: ends on 31 December
Annual meeting: 23 April at 14:00
deed of 13-12-2023 (in Dutch)
Peppol: Reachable since 18-11-2025Follow this company and you will hear the next morning if it leaves the Peppol register.
Name: DEVIDERMA in Dutch
Entity type: Legal entity
Duration: Unlimited
deed of 13-12-2023 (in Dutch)
Registered office clause: “Vlaams Gewest”
deed of 13-12-2023 (in Dutch)

Activities

NACEBEL 2025

86220 Specialist medical practice main activity

86995 Nutrition and dietetics services

Codes under NACEBEL 2008

86220 Human health activities main activity

86909 Human health activities

Purpose: “De uitoefening van de beroepsactiviteit door de arts-aandeelhouders in het domein van de dermatologie,in naam en voor rekening van de…”
7 activities
De uitoefening van de beroepsactiviteit door de arts-aandeelhouders in het domein van de dermatologie,in naam en voor rekening van de vennootschap,met inachtname van de regels van de medische deontologie,onder meer betreffende het beroepsgeheim.De activiteit omvat impliciet de inning en de uitkering van een vergoeding à rato van de voor rekening van de vennootschap geleverde prestaties
Het ter beschikking stellen van alle nodige middelen aan de arts-aandeelhouders en het aanwerven van medisch en paramedisch personeel ter ondersteuning van het verstrekken van medische zorgen
Het inrichten van algemene diensten,en een medisch secretariaat in het bijzonder,die nuttig of nodig zijn voor de uitoefening van voornoemde activiteiten
De aankoop,het huren en invoeren van alle medische apparatuur en begeleidende accommodaties voor voornoemde activiteiten
Het aanleggen van reserves om daarmee alle materiële infrastructuur aan te schaffen
De mogelijkheden scheppen om de arts-aandeelhouders toe te laten zich verder te bekwamen teneinde in zijn discipline aan de spits van de evolutie te blijven
De mogelijkheden scheppen voor de arts-aandeelhouders om op te treden als spreker of lesgever,in te staan voor het geven van lezingen op cursussen,seminaries en congressen in zijn discipline,en op te treden als auteur of uitgever van publicaties in zijn discipline
deed of 13-12-2023 (in Dutch)

Registered office and establishments

1 establishment

Establishment	Since	Unit number
Ganzenbos 24 registered office 1730 Asse	07-07-2009	2.182.243.444

Buildings and parcels at the address

Ground area: 965 m²
Buildings: 136 m²
Volume, LiDAR: 856 m³
Tallest building: 8.8 m

Buildings to scale, each on its own parcel

registered office establishment The establishment unit on the map

Parcels

Cadastral parcel	Area	Buildings	Height / floors
23041B0007/00L000	965 m²	1 · 136 m²	8.8 m · 2

Overview

Lifetime

Key points

Equity

Turnover

Debts

Investments

Liquidity

Filings

Checked score

Score breakdown

Comparable companies, two years later

Credit verdict

Signals

Board and ownership

Recent changes

Comparable companies

Official details

Annual accounts 2025

Insights on DEVIDERMA

Financials

Annual accounts 2025

Money flows

Balance sheet

Change in equityin euro

Change in cashin euro

Position in the sector

Solvency65.1%

Current ratio9.89

Return on assets9.3%

Filed annual accounts

Filings

Subsidies and aid

Flemish government 2024 to 2025, 2 entries, €2,328 awarded, €2,328 paid

Key figures and ratios

Investments

Insights on DEVIDERMA

Board & ownership

Board

Mandates through the years

Control

Capital

Articles of association

Network & group

No group

Timeline

Timeline

History

Company details

Identity

Activities

Registered office and establishments

Buildings and parcels at the address

Location

Parcels

in euro

in euro

65.1%

9.89

9.3%